Home › RLT targets by cancer › Colorectal Cancer
Radioligand therapy · Colorectal Cancer

Radioligand Therapy Targets in Colorectal Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in colorectal cancer (including colon and rectal adenocarcinoma). 4,461 show detectable protein staining. Established and emerging radioligand targets expressed in colorectal cancer include EPCAM, HER3 (ERBB3), CEA (CEACAM5) and c-MET (MET). Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own colorectal cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank colorectal cancer targets free

Established and emerging radioligand targets in colorectal cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in colorectal cancer:

TargetIHC in colorectal cancer% positiveInternalizes
EPCAMHigh (1.00)100%—
HER3 (ERBB3)High (0.87)100%yes
CEA (CEACAM5)High (0.87)100%—
c-MET (MET)High (0.86)100%yes
STEAP2High (0.83)100%—
FAPHigh (0.80)100%yes
SSTR2Medium (0.47)92%yes
EGFRMedium (0.44)83%yes
B7-H3 (CD276)Medium (0.39)83%—
ITGAVMedium (0.36)100%—
TMEFF2Medium (0.31)67%—
Nectin-4 (NECTIN4)Medium (0.30)80%no
HER2 (ERBB2)Medium (0.24)46%yes
Mesothelin (MSLN)Medium (0.21)27%yes
ITGB6Low (0.17)50%—
Claudin 18.2 (CLDN18)Low (0.11)17%uncertain
TROP2 (TACSTD2)Low (0.08)25%uncertain

Top cell-surface targets for colorectal cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in colorectal cancer% positiveInternalizesClinical stage
1c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
High (0.86)100%yesFDA-Approved
2NOTCH1
notch receptor 1
High (1.00)100%yesClinical
3IGF1R
insulin like growth factor 1 receptor
High (0.90)100%yesFDA-Approved
4HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.87)100%yesFDA-Approved
5NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.97)100%uncertainFDA-Approved
6CYSLTR2
cysteinyl leukotriene receptor 2
High (0.92)100%yesDiscovery
7EPHB2
EPH receptor B2
High (0.83)100%uncertainFDA-Approved
8FZD3
frizzled class receptor 3
High (0.97)100%yesDiscovery
9IRAK4
interleukin 1 receptor associated kinase 4
High (0.82)100%yesClinical
10S1PR1
sphingosine-1-phosphate receptor 1
Medium (0.47)100%yesFDA-Approved
11GABRE
gamma-aminobutyric acid type A receptor subunit epsilon
High (1.00)100%uncertainFDA-Approved
12ADGRL1
adhesion G protein-coupled receptor L1
High (0.94)100%yesDiscovery
13EGFR
epidermal growth factor receptor
Medium (0.44)83%yesFDA-Approved
14EPHB4
EPH receptor B4
High (0.67)92%yesFDA-Approved
15FZD6
frizzled class receptor 6
High (0.92)100%yesDiscovery
16CHRM2
cholinergic receptor muscarinic 2
High (0.88)100%uncertainFDA-Approved
17GPR4
G protein-coupled receptor 4
High (0.77)90%yesDiscovery
18AMFR
autocrine motility factor receptor
High (0.92)92%yesDiscovery
19NOTCH3
notch receptor 3
High (0.69)100%yesClinical
20HRH4
histamine receptor H4
High (0.72)100%yesClinical
21CHRNA7
cholinergic receptor nicotinic alpha 7 subunit
High (0.70)100%yesClinical
22FGFR1
fibroblast growth factor receptor 1
High (0.56)100%yesFDA-Approved
23MAOB
monoamine oxidase B
High (0.86)100%—FDA-Approved
24M6PR
mannose-6-phosphate receptor, cation dependent
High (0.86)100%yesDiscovery
25IL1R2
interleukin 1 receptor type 2
High (0.67)100%yesDiscovery

Internalizing receptors in colorectal cancer

Targets expressed in colorectal cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

c-MET (MET) · NOTCH1 · IGF1R · HER3 (ERBB3) · CYSLTR2 · FZD3 · IRAK4 · S1PR1 · ADGRL1 · EGFR · EPHB4 · FZD6

Colorectal Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in colorectal cancer. Clinical precedent lowers development risk but usually means more competition:

c-MET (MET) · NOTCH1 · IGF1R · HER3 (ERBB3) · NR3C2 · EPHB2 · IRAK4 · S1PR1 · GABRE · EGFR · EPHB4 · CHRM2

How these colorectal cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in colorectal cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank colorectal cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free colorectal cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist colorectal cancer targets for your program · 5 free analyses, no card Rank colorectal cancer targets free